Should Asymptomatic Bacteriuria Be Systematically Treated in Kidney Transplant Recipients? Results From a Randomized Controlled Trial

详细信息    查看全文

• 作者：J. Origü ; en ; F. Ló ; pez-Medrano ; M. Ferná ; ndez-Ruiz ; N. Polanco ; E. Gutié ; rrez ; E. Gonzá ; lez ; E. Mé ; rida ; T. Ruiz-Merlo ; A. Morales-Cartagena ; M. A. Pé ; rez-Jacoiste Así ; n ; A. Garcí ; a-Reyne ; R. San Juan ; M. Á ; . Orellana ; A. André ; s and J. M. Aguado
• 刊名：American Journal of Transplantation
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：16
• 期：10
• 页码：2943-2953
• 全文大小：173K
• ISSN：1600-6143

文摘

The indication for antimicrobial treatment of asymptomatic bacteriuria (AB) after kidney transplantation (KT) remains controversial. Between January 2011 and December 2013, 112 KT recipients that developed one episode or more of AB beyond the second month after transplantation were included in this open-label trial. Participants were randomized (1:1 ratio) to the treatment group (systematic antimicrobial therapy for all episodes of AB occurring ≤24 mo after transplantation [53 patients]) or control group (no antimicrobial therapy [59 patients]). Systematic screening for AB was performed similarly in both groups. The primary outcome was the occurrence of acute pyelonephritis at 24-mo follow-up. Secondary outcomes included lower urinary tract infection, acute rejection, Clostridium difficile infection, colonization or infection by multidrug-resistant bacteria, graft function and all-cause mortality. There were no differences in the primary outcome in the intention-to-treat population (7.5% [4 of 53] in the treatment group vs. 8.4% [5 of 59] in the control group; odds ratio [OR] 0.88, 95% confidence interval [CI] 0.22–3.47) or the per-protocol population (3.8% [1 of 26] in the treatment group vs. 8.0% [4 of 50] in the control group; OR 0.46, 95% CI 0.05–4.34). Moreover, we found no differences in any of the secondary outcomes. In conclusion, systematic screening and treatment of AB beyond the second month after transplantation provided no apparent benefit among KT recipients (NCT02373085).